Form 4: Alkermes COO Jackson Exercises RSUs, Sells Shares for Tax

Alkermes plc's EVP and Chief Operating Officer, Blair Curtis Jackson, acquired 8,738 ordinary shares through a restricted stock unit award vesting and subsequently sold 3,880 shares to cover tax obligations.

Summary

• Blair Curtis Jackson, EVP, Chief Operating Officer of Alkermes plc, acquired 8,738 ordinary shares on February 23, 2026, through the vesting of a restricted stock unit award.
• Concurrently, Jackson disposed of 3,880 ordinary shares at a price of $32.19 per share on February 23, 2026, to satisfy tax withholding obligations related to the vesting of the restricted stock units.
• Following these transactions, Jackson directly holds 236,681 ordinary shares.
• Jackson also continues to beneficially own 8,738 restricted stock units, which represent a contingent right to receive one ordinary share each. These RSUs vest in four equal annual installments, with the first installment commencing on February 23, 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While there's a sale of shares, it's for tax purposes, which is routine. The underlying acquisition of shares from vesting and the significant remaining beneficial ownership indicate continued alignment with shareholder interests.

Positives

• The acquisition of 8,738 ordinary shares indicates the vesting of previously granted equity compensation, aligning management's interests with shareholders.
• The retention of a significant number of shares (236,681) after the tax-related sale suggests continued confidence in the company's long-term prospects.

Negatives

• The sale of 3,880 shares, while for tax purposes, represents a reduction in direct ownership, albeit a common practice for equity compensation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to equity compensation vesting and subsequent tax-related sales, are common occurrences in the pharmaceutical and biotechnology industry. These transactions often reflect pre-scheduled compensation events rather than discretionary investment decisions, making their direct impact on broader industry trends limited unless they involve unusually large, non-tax-related sales.

Comparison to Industry Standards

• Insider transactions involving the exercise of equity awards and subsequent sales to cover tax obligations are standard practice across industries, including pharmaceuticals. For example, executives at companies like Pfizer or Johnson & Johnson frequently report similar Form 4 filings when their stock options or restricted stock units vest.
• The sale of 3,880 shares out of 8,738 acquired (approximately 44%) for tax purposes is a typical percentage, reflecting standard income tax rates on equity compensation.

Stakeholder Impact

• Shareholders: The vesting of RSUs and the executive's continued significant ownership align management's interests with shareholders, potentially fostering long-term value creation. The tax-related sale is a routine event and not indicative of a lack of confidence.
• Employees: This filing demonstrates the company's ongoing equity compensation program for its executives, which can be a positive signal for employee retention and motivation.

Next Steps

• The remaining 8,738 restricted stock units are expected to vest in the future, likely on February 23, 2027, as part of the four equal annual installments.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation vesting and tax withholding. It does not provide new fundamental information about Alkermes plc's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and do not signal a significant shift in insider sentiment beyond the standard management of equity awards. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific filing.

Keywords

Alkermes plc, ALKS, Blair Curtis Jackson, EVP, Chief Operating Officer, Insider Transaction, Form 4, Restricted Stock Units, RSU, Equity Compensation, Share Vesting, Tax Withholding, Beneficial Ownership